Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimeporide in Duchenne Muscular Dystrophy
NCT02710591Phase 1Completed
- Sponsor
- EspeRare
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of rimeporide in Duchenne muscular dystrophy (DMD), sponsored by EspeRare. Primary endpoint: Number of Participants With Adverse Events at 6 weeks. Started Mar 2016; status: completed.
02
Drugs
rimeporide
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02710591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710591.